Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2024-11-13

FDA Approved: SUNLENCA — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Sunlenca (lenacapavir sodium) from Gilead Sciences, Inc., updating the drug’s labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SUNLENCA (LENACAPAVIR SODIUM)

Snippet

SUPPL AP for SUNLENCA (LENACAPAVIR SODIUM)